We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.14 | 2.10 | 2.18 | 2.20 | 2.19 | 2.19 | 604,698 | 16:35:15 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.81M | -0.0114 | -1.93 | 7.33M |
TIDMIMM TIDMLGEN
RNS Number : 6800O
Immupharma PLC
09 November 2016
RNS : FOR IMMEDIATE RELEASE 9 NOVEMBER 2016
NOTIFICATION OF MAJOR INTEREST BY LEGAL & GENERAL
ImmuPharma PLC (LSE:IMM) ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces that it has received notification by Legal & General Group Plc ("L&G") confirming its holding in ImmuPharma of 4,285,714 million Ordinary Shares in the capital of the Company, representing 3.43% of ImmuPharma's total voting rights.
Commenting, Tim McCarthy, Chairman of ImmuPharma, said: "We are delighted to be able to disclose Legal & General as one of the new significant and major institutional investors which participated in ImmuPharma's recent successful vendor placing. One of the Board's priorities is to maintain and strengthen our shareholder base. We are therefore delighted that such a highly regarded institution as Legal & General has demonstrated its support for ImmuPharma."
Full disclosure of the TR1 is shown below:
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES -------------------------------------------------------------------------------------------------- 1. Identity of the issuer or Immupharma Plc the underlying issuer of existing shares to which voting rights are attached: ------------------------------------------------------------ ------------------------------------ 2. Reason for the notification (please tick the appropriate box or boxes): -------------------------------------------------------------------------------------------------- An acquisition or disposal of voting rights Yes -------------------------------------------------------------------------------------------- ---- An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached. -------------------------------------------------------------------------------------------- ---- An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments -------------------------------------------------------------------------------------------- ---- An event changing the breakdown of voting rights Yes -------------------------------------------------------------------------------------------- ---- Other (please Placement of 2,857,143 shares specify): -------------------------------------------------------- ---------------------------------- ---- 3. Full name of person(s) Legal & General Group Plc subject to the (L&G) notification obligation: ---------------------------------------------------------- -------------------------------------- 4. Full name of shareholder(s) (if different from 3.): Legal & General Assurance Society Limited (LGAS & LGPL) ---------------------------------------------------------- -------------------------------------- 21 October 2016 5. Date of the transaction and date on which the threshold is crossed or reached: ---------------------------------------------------------- -------------------------------------- 6. Date on which issuer 28 October 2016 notified: ---------------------------------------------------------- -------------------------------------- 7. Threshold(s) that is/are L&G (Above 3%) crossed or reached: ---------------------------------------------------------- -------------------------------------- 8. Notified details: -------------------------------------------------------------------------------------------------------------------------------- A: Voting rights attached to shares -------------------------------------------------------------------------------------------------------------------------------- Class/type Situation previous Resulting situation after the of to the triggering triggering transaction shares transaction if possible using the ISIN CODE ------------ ------------------------------------------------ ---------------------------------------------------------------- Number Number Number of voting % of voting of of rights rights Shares Voting Rights ------------ ---------------- ------------------------------ -------------------------- --------------------- Number Direct Indirect Direct Indirect of shares ------------ ------------ ------------ ------------ ------------- ------------- ----------- --------- ---------- ORD GBP First notification 0.10 under DTR Sourcebook 4,285,714 4,285,714 - 3.43% - ------------ ------------------------------------------------ ------------- ------------- ----------- --------- ---------- B: Qualifying Financial Instruments -------------------------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction -------------------------------------------------------------------------------------------------------------------------------- Number of voting Type of Expiration Exercise/ rights that % of voting financial date Conversion may be rights instrument Period acquired if the instrument is exercised/ converted. ---------------- ---------------- ------------------------------------------- -------------------------- ------------------- C: Financial Instruments with similar economic effect to Qualifying Financial Instruments -------------------------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction -------------------------------------------------------------------------------------------------------------------------------- Type of Exercise Expiration Exercise/ Number of voting % of voting financial price date Conversion rights instrument rights instrument period refers to -------------- ---------------- -------------- -------------- ---------------------------- -------------------------------- Nominal Delta -------------- ---------------- -------------- -------------- ---------------------------- -------------------- ---------- Total (A+B+C) -------------------------------------------------------------------------------------------------------------------------------- Number of voting rights Percentage of voting rights ---------------------------------------------------------------- -------------------------------------------------------------- 4,285,714 3.43% ---------------------------------------------------------------- -------------------------------------------------------------- 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: -------------------------------------------------------------------------------------------------------------------- Legal & General Group Plc (Direct and Indirect) (Group) (Below 5% = Total Position) Legal & General Investment Management (Holdings) Limited (LGIMH) (Direct and Indirect) (Below 5% = Total Position)
Legal & General Investment Management Limited (Indirect) (LGIM) (Below 5% = Total Position) Legal & General Group Plc (Direct) (L&G) (4,285,714, 3.43% = LGAS, LGPL & PMC) Legal & General Investment Management Legal & General Insurance Holdings Limited (Holdings) Limited (Direct) (LGIMHD) (Direct) (LGIH) (4,285,714, 3.43% = LGAS & LGPL) Legal & General Assurance (Pensions Legal & General Assurance Society Limited Management) Limited (PMC) (LGAS & LGPL) (4,285,714, 3.43% = LGAS & LGPL) Legal & General Pensions Limited (Direct) (LGPL) Proxy Voting: -------------------------------------------------------------------------------------------------------------------- 10. Name of the proxy holder: N/A ----------------------------------------------------------------------------- ------------------------------------- 11. Number of voting rights proxy N/A holder will cease to hold: ----------------------------------------------------------------------------- ------------------------------------- 12. Date on which proxy holder will N/A cease to hold voting rights: ----------------------------------------------------------------------------- ------------------------------------- Notification using the total 13. Additional information: voting rights figure of 124,638,362 ----------------------------------------------------------------------------- ------------------------------------- 14. Contact name: Victoria Davies (LGIM) ----------------------------------------------------------------------------- ------------------------------------- 15. Contact telephone number: 029 2035 4147 ----------------------------------------------------------------------------- -------------------------------------
-Ends-
For further information please contact: + 44 (0) 20 ImmuPharma plc (www.immupharma.org) 7152 4080 Tim McCarthy, Chairman Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 Twitter: @immupharma 413496 Panmure, Gordon & Co., (NOMAD +44 (0) 20 & Broker) 7886 2500 Freddy Crossley, Duncan Monteith, Corporate Finance Charles Leigh-Pemberton, Corporate Broking Northland Capital Partners Limited (Joint Broker) Patrick Claridge, David Hignell, Corporate Finance Rob Rees, John Howes, Corporate +44 (0)20 3861 Broking 6625
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLBVLLBQFFLFBQ
(END) Dow Jones Newswires
November 09, 2016 02:01 ET (07:01 GMT)
1 Year Immupharma Chart |
1 Month Immupharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions